DFTX · Definium Therapeutics, Inc. · Executive Compensation

$33.00 -1.47 (-4.26%) At close · Nov 12 Play latest call Q3 2026 earnings call transcript

Russell 2000 member Rebalance outlook locked

Market Cap

$4.52B

136.90M

Volume · Nov 12 1.2M Avg daily vol (3M) 2M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Robert Barrow	Chief Executive Officer	$655,000	—	$11,719,750	—	$378,263	$14,429	$12,767,442
Brandi L. Roberts	Chief Financial Officer	$288,750	—	$1,815,000	$2,890,889	$121,322	$401	$5,116,362
Daniel Karlin	Chief Medical Officer	$510,000	—	$3,262,525	—	$214,200	$14,533	$4,001,258

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Robert Barrow	Chief Executive Officer	$623,500	—	—	$1,672,000	$359,216	$14,294	$2,669,010
Daniel Karlin	Chief Medical Officer	$485,500	$0	$0	$627,000	$203,424	$14,395	$1,330,319
Mark Sullivan	J.D. Chief Legal Officer	$439,750	$0	$0	$522,500	$184,288	$14,569	$1,161,107

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark Sullivan	J.D. Chief Legal Officer	$308,167	$0	$596,000	$0	$163,400	$12,827	$1,080,394
Daniel Karlin	Chief Medical Officer	$462,500	$0	$378,750	$0	$180,500	$15,522	$1,037,272

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
JR Rahn	Former Chief Executive Officer	$213,333	—	$8,573,655	$4,959,212	—	$1,245,152	$14,991,351
Robert Barrow	Chief Executive Officer	$350,000	$358,411	$5,798,040	$5,383,015	—	—	$11,889,466
Daniel Karlin	Chief Medical Officer	$291,667	$175,000	$2,467,920	$1,971,355	—	—	$4,905,942
Miri Halperin Wernli	Executive President	$377,464	$175,000	$1,146,600	$964,464	—	—	$2,663,528
Stephen Hurst	Former Co-Chief Executive Officer	$118,333	—	$55,000	$46,607	—	$839,375	$1,059,315

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
JR Rahn	Former Chief Executive Officer	$266,667	—	—	$967,826	—	—	$1,234,493
Miri Halperin Wernli	Executive President	$131,292	$72,939	—	$791,916	—	—	$996,147

Executive changes

Person	Role	Change	Effective	Filed
Roger Adsett	Director	Appointed	2026-06-11	2026-06-12
Carol A. Vallone	Director	Appointed	2026-06-11	2026-06-12
David Gryska	Director	Appointed	2026-06-11	2026-06-12
Andreas Krebs	Director	Appointed	2026-06-11	2026-06-12
Suzanne Bruhn	Director	Appointed	2026-06-11	2026-06-12
Roger Crystal	Director	Appointed	2026-06-11	2026-06-12
Robert Barrow	Director	Appointed	2026-06-11	2026-06-12
Roger Adsett	director	Appointed	2026-01-29	2026-01-29
David Gryska	member of the Board	Appointed	2025-06-12	2025-06-16
Andreas Krebs	member of the Board	Appointed	2025-06-12	2025-06-16
Carol A. Vallone	member of the Board	Appointed	2025-06-12	2025-06-16
Suzanne Bruhn	member of the Board	Appointed	2025-06-12	2025-06-16
Roger Crystal	member of the Board	Appointed	2025-06-12	2025-06-16
Robert Barrow	member of the Board	Appointed	2025-06-12	2025-06-16
Brandi L. Roberts	Chief Financial Officer	Appointed	2025-06-02	2025-05-27
Miri Halperin Wernli	Executive President	Terminated	2025-02-28	2025-01-13
Roger Crystal	Director	Appointed	2022-08-11	2022-08-11
Suzanne Bruhn	Director	Appointed	2022-08-11	2022-08-11
Miri Halperin Wernli	Director	Resigned	2022-08-11	2022-08-11

Leadership

Dr. Roger Crystal CEO
Dr. Suzanne Bruhn CEO
JR Rahn CEO
Robert Barrow CEO
Stephen Hurst CEO
Carol A. Vallone Chairman
Brandi L. Roberts CFO
David Gryska CFO
Roger Adsett COO, Board Member
Carrie F. Liao Chief Accounting Officer
Andreas Krebs Board Member
Roger Crystal Board Member
Roger Crystal, M.D. Board Member
Suzanne Bruhn Board Member
Suzanne Bruhn, Ph.D. Board Member

Key facts CIK 1813814 CUSIP 24477V105 13F (30d) 192 filings 190 filers Visit website Investor relations